Table 3.

Significant HPV vaccine outcomes among quasi-experimental interventions

Study Design	Quasi-experimental type	Vaccine Outcomes (VI, VC, Both)	Significance	Multi Component	Multi Level
Quasi-experimental (n = 16)	Comparison groups [53, 60, 65, 86, 92] ( n  = 5; 31.3%)	3 (60.0%) measured Vaccine Initiation (VI) [60, 65, 92]	2 (40.0%) found a significant increase for VI [60, 92]
		None for Vaccine Completion (VC)	aNA
		1 (20.0%) measured Vaccine Initiation and Vaccine Completion (both) [53]	1 (20.0%) found both significantly increased [53]
			Total Significance: 3 articles had a significant increase in either VI or both [53, 60, 92]	3 (100%) were multi component studies [53, 60, 92]	2 (66.7%) were multi-level [53, 92]
	Pre/Post Test [20, 21, 28, 37, 61, 66, 69, 70, 83, 87, 89] (n = 11; 68.8%)	2 (18.2%) measured Vaccine Initiation (VI) [28, 70]	1 (9.1%) found a significant increase for VI [28]
		1 (9.1%) measured vaccine completion (VC) [61]	1 (9.1%) found a significant increase for VC [61]
		4 (36.4%) measured both [20, 66, 69, 89]	2 (18.2%) found a significant increase for both [66, 69]
			Total Significance: 4 total articles had significant increases in either VI, VC, or both [28, 61, 66, 69]	2 (50.0%) studies were multi component [28, 61]	3 (75.0%) were multi-level [28, 61, 69]

^a NA Not applicable